

PHARMACIA CORP /DE/
Form 5
February 15, 2002

FORM 5

Check box if no longer subject to
Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).

Form 3 Holdings Reported

Form 4 Transactions Reported

OMB APPROVAL

OMB Number: 323
Expires: December 31
Estimated average bu
hours per response..

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of t
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of

-----			2. Issuer Name and Ticker
1. Name and Address of Reporting Person*			Pharmacia Co
Leder	Philip		
(Last)	(First)	(Middle)	3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)
	100 Route 206 North		
	(Street)		
Peapack,	NJ	07977	
(City)	(State)	(Zip)	

6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director 10% Owner

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

----- Officer (give title below) ----- Other (specify below)

7. Individual or Joint/Group Reporting
(check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans- action Date (Month/ Day/ Year)	3. Trans- action Code (Instr. 8)	4. Securities or Disposed (Instr. 3, Amount
Common	04/17/2001	A	2,200

5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
11,283 (1)	D	

*If the form is filed by more than one reporting person, see

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

instruction 4(b)(v).

(Over)
SEC 2270 (3-99)

Page 1 of 3

FORM 5 (continued)

Leder, Philip--December 2001

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date and (Month)
				(A)	(D)	
Option (right to buy)	\$55.00					(
Option (right to buy)	\$44.25					(
Stock Equivalent Units	1-for-1					
7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Year	10. Ownership of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 3)		

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

(Instr. 4)

Title	Amount or Number of Shares		
Common	12,690	12,690	D
Common	13,636	13,636	D
Common	2,232	2,232 (3)	D

Explanation of Responses:

See attached statement

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Don W. Schmitz	2/14/2002
-----	-----
** Signature of Reporting Person Don W. Schmitz, attorney-in-fact for Philip Leder	Date

Page 2
SEC 2270 (3-99)

Page 2 of 3

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

Form 5 - December 2001

Leder, Philip

100 Route 206 North

Peapack, NJ 07977

Explanation of responses:

- (1) Includes 58 shares acquired through the reinvestment of dividends since last reported to the SEC.
- (2) Option is currently exercisable.
- (3) Includes 2,200 shares held in a Deferred Director's Compensation Plan, and 32 dividend equivalents on such shares.

Page 3 of 3